The C terminus of p53 binds the N-terminal domain of MDM2
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
The p53 tumor suppressor interacts with its negative regulator Mdm2 via the former's N-terminal region and core domain, yet the extreme p53 C-terminal region contains lysine residues ubiquitinated by Mdm2 and can bear post-translational modifications that inhibit Mdm2-p53 association. We show that the Mdm2-p53 interaction is decreased upon deletion, mutation or acetylation of the p53 C terminus. Mdm2 decreases the association of full-length but not C-terminally deleted p53 with a DNA target sequence in vitro and in cells. Further, using multiple approaches, we show that a peptide from the p53 C terminus directly binds the Mdm2 N terminus in vitro. We also show that p300-acetylated p53 inefficiently binds Mdm2 in vitro, and Nutlin-3 treatment induces C-terminal modification(s) of p53 in cells, explaining the low efficiency of Nutlin-3 in dissociating p53-MDM2 in vitro.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · cited 1×
“Biologically active inhibitors of this interaction (such as Nutlin-3) have been developed with the goal of dissociating p53 from Mdm2 and activating p53 in abnormally proliferating cell”
BackgroundMdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
Blinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163 · cited 1×
“The activity of p53 is tightly regulated in cells through post-translational modifications, localization and degradatio”
BackgroundSelf-citationDNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,551 · cited 1×
“p53 coexpressed with p300 is highly acetylated, as shown by a gain of reactivity with a Pan-acetyl antibody and corresponding loss of reactivity with an antibody PAb 421 that recognizes unmodified p53 CTD 372–382 (refs”
BackgroundStructure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206
DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2
Shieh, S.-Y., Ikeda, M., Taya, Y., & Prives, C. (1997) · Cell · doi:10.1016/s0092-8674(00)80416-x · Cited by 2,100 · cited 1×
“Upon various forms of DNA damage, the TAD-I of p53 is modified by upstream protein kinases on several residues that weaken its interaction with Mdm2 (refs”
BackgroundSelf-citationActivation of the DNA damage checkpoint and genomic instability in human precancerous lesions
Gorgoulis, V. G., Vassiliou, L.-V. F., Karakaidos, P., Zacharatos, P., Kotsinas, A., Liloglou, T., Venere, M., DiTullio, R. A., Kastrinakis, N. G., Levy, B., et al. (2005) · Nature · doi:10.1038/nature03485 · Cited by 2,009
Shieh, S.-Y., Ahn, J., Tamai, K., Taya, Y., & Prives, C. (2000) · Genes & Development · doi:10.1101/gad.14.3.289 · Cited by 972
Self-citationAcetylation Is Indispensable for p53 Activation
Tang, Y., Zhao, W., Chen, Y., Zhao, Y., & Gu, W. (2008) · Cell · doi:10.1016/j.cell.2008.03.025 · Cited by 838
Cited by
Mechanisms of transcriptional regulation by p53
Sullivan, K. D., Galbraith, M. D., Andrysik, Z., & Espinosa, J. M. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.174 · Cited by 446
The MDM2-p53 pathway revisited
Subhasree, N., Jiangjiang, Q., Kalkunte, S., Minghai, W., & Ruiwen, Z. (2013) · The Journal of Biomedical Research · doi:10.7555/jbr.27.20130030 · Cited by 414
Targeting p53 for the treatment of cancer
Duffy, M. J., Synnott, N. C., O’Grady, S., & Crown, J. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.005 · Cited by 349
The Roles of MDM2 and MDMX in Cancer
Karni-Schmidt, O., Lokshin, M., & Prives, C. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040349 · Cited by 296
Self-citationTRIM67 Activates p53 to Suppress Colorectal Cancer Initiation and Progression
Wang, S., Zhang, Y., Huang, J., Wong, C. C., Zhai, J., Li, C., Wei, G., Zhao, L., Wang, G., Wei, H., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3614 · Cited by 104
Metadata
- Authors
- Poyurovsky, M. V., Katz, C., Laptenko, O., Beckerman, R., Lokshin, M., Ahn, J., Byeon, I.-J. L., Gabizon, R., Mattia, M., Zupnick, A., Brown, L. M., Friedler, A., & Prives, C.
- Venue
- Nature Structural & Molecular Biology
- Published
- 2010-07-18
- Volume
- 17
- Issue
- 8
- Pages
- 982-989
- ISSN
- 1545-9985 (ISSN-L)
- 1545-9993
- OpenAlex
- W2029343580
- Cited by
- 149
- References
- 18
- FWCI
- 5.70
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The C terminus of p53 binds the N-terminal domain of MDM2. https://app.cochat.ai/papers/10.1038/nsmb.1872
- The paper
- Poyurovsky, M. V., Katz, C., Laptenko, O., Beckerman, R., Lokshin, M., Ahn, J., Byeon, I.-J. L., Gabizon, R., Mattia, M., Zupnick, A., Brown, L. M., Friedler, A., & Prives, C. (2010). The C terminus of p53 binds the N-terminal domain of MDM2. Nature Structural & Molecular Biology. https://doi.org/10.1038/nsmb.1872
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.